Positive vascular
Benefits:

DECREASED
Endothelin - Potent vasoconstrictor - Werner et al. 1998 - Wu GF et al. Circulation 1999

DECREASED
BNP - Promotes diuresis -Released with LV dysfunction - Urano et al. JACC Jan 2001 - Masuda, et al., Euro Heart J 2001

INCREASED
Nitric Oxide -Potent vasodilator - Xiao-Xian Qian et al. 1999 - Wu GF et al. Circulation 1999 - Qian XX et al. J Heart Dis 1999 - Masuda D. et al. Eur Heart J 2001

INCREASED
VEGF -Promotes angiogenesis Masuda et al. Euro Heart J 2001

INCREASED
ANP-Promotes diuresis - Kho et al. Endocrine Society’s 82nd Annual Meeting 2000 - Masuda et al. Euro Heart J 2001

Additional clinical benefits:

Improvement in peak oxygen consumption (Soran et al)
Increased ejection fraction (Gorscan et al, Suresh et al, Strobeck et al)
Increased cardiac output (Gorscan et al, Suresh et al)
Decreased heart rate (Gorscan et al)
Improvement in exercise times (Soran et al)
Improvements in quality of life (Soran et al)
Reduction in CCS angina classification immediately after therapy (Arora et al)
Up to 85% decrease at least 1 class
Up to 54% decrease at least 2 classes
Decreased anginal episodes and nitroglycerin use (Suresh et al, Int. ECP Pat. 
   Reg.)
Improvement sustained for up to 5 years (Feldman, Lawson, Cohn et al)